{"id":"aranesp-darbepoetin-alfa","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"5-15","effect":"Thrombovascular events (stroke, myocardial infarction, venous thromboembolism)"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Arthralgia"},{"rate":"5-10","effect":"Injection site pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Darbepoetin alfa is a recombinant human erythropoietin analog engineered with two additional N-linked carbohydrate chains, which extends its half-life compared to epoetin alfa. It binds to erythropoietin receptors on erythroid progenitor cells in the bone marrow, activating JAK2 signaling and promoting proliferation, differentiation, and maturation of red blood cells. This mechanism increases hemoglobin levels and reduces the need for blood transfusions in patients with anemia.","oneSentence":"Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:34.026Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in patients with non-myeloid malignancies receiving chemotherapy"},{"name":"Anemia of chronic disease"}]},"trialDetails":[{"nctId":"NCT07119372","phase":"PHASE3","title":"Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Biocad","startDate":"2025-03-01","conditions":"Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis","enrollment":228},{"nctId":"NCT05636891","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis","status":"COMPLETED","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","startDate":"2021-09-19","conditions":"Chronic Kidney Disease","enrollment":43},{"nctId":"NCT05585645","phase":"PHASE3","title":"A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)","status":"COMPLETED","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","startDate":"2019-08-08","conditions":"Anemia, Chronic Kidney Disease Requiring Chronic Dialysis","enrollment":214},{"nctId":"NCT02278341","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-11-21","conditions":"Anemia, End Stage Renal Disease (ESRD)","enrollment":838},{"nctId":"NCT05265325","phase":"PHASE2","title":"A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis","status":"COMPLETED","sponsor":"Kind Pharmaceuticals LLC","startDate":"2023-05-03","conditions":"Renal Anemia","enrollment":175},{"nctId":"NCT06466785","phase":"PHASE3","title":"A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Genexine, Inc.","startDate":"2024-01-25","conditions":"Anemia of Chronic Kidney Disease","enrollment":429},{"nctId":"NCT05864261","phase":"PHASE4","title":"Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers","status":"COMPLETED","sponsor":"Yi Fang","startDate":"2023-05-15","conditions":"Renal Anemia","enrollment":74},{"nctId":"NCT00858364","phase":"PHASE3","title":"Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy","status":"TERMINATED","sponsor":"Amgen","startDate":"2009-07-17","conditions":"Non-Small Cell Lung Cancer, Anemia, Cancer","enrollment":2549},{"nctId":"NCT00436748","phase":"PHASE3","title":"Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease","status":"TERMINATED","sponsor":"Amgen","startDate":"2008-09-16","conditions":"Anemia, Chronic Kidney Disease, Kidney Disease","enrollment":116},{"nctId":"NCT00093015","phase":"PHASE3","title":"Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08-01","conditions":"Kidney Disease, Diabetes Mellitus, Anemia","enrollment":4038},{"nctId":"NCT00358215","phase":"PHASE3","title":"RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-06-01","conditions":"Heart Failure, Anemia, Cardiovascular Disease","enrollment":2278},{"nctId":"NCT04484857","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-07-22","conditions":"Anemia Associated With End Stage Renal Disease","enrollment":283},{"nctId":"NCT02273726","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2015-01-15","conditions":"CKD Anemia in Stable Dialysis Patients","enrollment":741},{"nctId":"NCT00153868","phase":"PHASE4","title":"A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2003-10","conditions":"Anemia, Cancer","enrollment":43},{"nctId":"NCT02241200","phase":"PHASE1","title":"A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2014-08-18","conditions":"Symptomatic Anemia","enrollment":64},{"nctId":"NCT02506868","phase":"PHASE3","title":"Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Biocad","startDate":"2015-08-08","conditions":"Chronic Kidney Disease, End Stage Renal Failure on Dialysis, Anemia","enrollment":196},{"nctId":"NCT03693950","phase":"PHASE1","title":"The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2017-03-28","conditions":"Healthy","enrollment":57},{"nctId":"NCT00773513","phase":"PHASE4","title":"A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-12-12","conditions":"Chronic Renal Anemia","enrollment":2825},{"nctId":"NCT02731469","phase":"PHASE1","title":"Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2016-06-15","conditions":"Reticulocyte Count","enrollment":45},{"nctId":"NCT02175277","phase":"PHASE3","title":"Darbepoetin Alfa MDS Companion Protocol","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-06-12","conditions":"Myelodysplastic Syndrome (MDS)","enrollment":9},{"nctId":"NCT02439697","phase":"NA","title":"A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-11","conditions":"Anemia, End Stage Renal Failure on Dialysis","enrollment":50},{"nctId":"NCT03542916","phase":"PHASE1","title":"Pharmacokinetics Study of CJ-40001 and NESP® After Single Dose Administration in Health Male Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2014-10","conditions":"Healthy Subjects","enrollment":56},{"nctId":"NCT01444456","phase":"","title":"Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-10","conditions":"Anemia, Breast Cancer, Cancer","enrollment":1262},{"nctId":"NCT00377481","phase":"PHASE4","title":"COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-09","conditions":"Anemia","enrollment":48},{"nctId":"NCT02506881","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2013-03","conditions":"Healthy","enrollment":74},{"nctId":"NCT00381836","phase":"PHASE2, PHASE3","title":"Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2006-10","conditions":"Prostatic Neoplasms, Anemia","enrollment":140},{"nctId":"NCT00364845","phase":"PHASE3","title":"STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients","status":"TERMINATED","sponsor":"Amgen","startDate":"2006-09","conditions":"Anemia, Chronic Kidney Disease","enrollment":51},{"nctId":"NCT00989092","phase":"PHASE2","title":"Darbepoetin Alfa and Anemia of Cancer","status":"TERMINATED","sponsor":"Amgen","startDate":"2002-05","conditions":"Anemia, Anemia of Cancer, Cancer","enrollment":287},{"nctId":"NCT00401544","phase":"PHASE2","title":"Darbepoetin Alfa With or Without Intravenous (IV) Iron","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-12","conditions":"Anemia, Non-Myeloid Malignancies","enrollment":243},{"nctId":"NCT00144131","phase":"PHASE2","title":"Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-08","conditions":"Anemia, Cancer","enrollment":750},{"nctId":"NCT00135317","phase":"PHASE3","title":"AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-11","conditions":"Cancer","enrollment":""},{"nctId":"NCT00117065","phase":"PHASE4","title":"Study of Transplant Related Anemia Treated With Aranesp® (STRATA)","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Anemia","enrollment":""},{"nctId":"NCT00375869","phase":"PHASE2","title":"Safety of Darbepoetin Alfa Treatment in Patients With Severe Traumatic Brain Injury","status":"COMPLETED","sponsor":"Royal Alexandra Hospital","startDate":"2006-11","conditions":"Traumatic Brain Injury","enrollment":10},{"nctId":"NCT00442702","phase":"PHASE3","title":"A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-09","conditions":"Anemia","enrollment":228},{"nctId":"NCT00117130","phase":"PHASE4","title":"Study to Evaluate Effectiveness of Aranesp®","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Kidney Disease","enrollment":""},{"nctId":"NCT00117104","phase":"PHASE4","title":"Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"End Stage Renal Disease","enrollment":""},{"nctId":"NCT00096915","phase":"PHASE3","title":"Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-10","conditions":"Kidney Disease, Chronic Kidney Disease","enrollment":110},{"nctId":"NCT00117117","phase":"PHASE4","title":"A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-09","conditions":"Anemia","enrollment":2423},{"nctId":"NCT00117039","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-01","conditions":"Anemia, Neoplasms","enrollment":1500},{"nctId":"NCT00117078","phase":"PHASE4","title":"Aranesp® Monthly Preference Study - 2","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Kidney Disease","enrollment":""},{"nctId":"NCT00111995","phase":"PHASE4","title":"Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"2002-05","conditions":"Chronic Renal Failure, Anemia","enrollment":400},{"nctId":"NCT00124098","phase":"PHASE3","title":"An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Amgen","startDate":"","conditions":"Kidney Disease","enrollment":""},{"nctId":"NCT00116701","phase":"PHASE3","title":"Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-05","conditions":"Kidney Disease","enrollment":200},{"nctId":"NCT00210002","phase":"PHASE2","title":"Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced","status":"TERMINATED","sponsor":"Institut Claudius Regaud","startDate":"2003-11","conditions":"Neoplasms, Anemia","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Aranesp® (darbepoetin alfa)","genericName":"Aranesp® (darbepoetin alfa)","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia in patients with non-myeloid malignancies receiving chemotherapy, Anemia of chronic disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}